Key investment points
The number of Sci-tech Innovation Board enterprises exceeded 400, and the transactions of professional investors accounted for nearly 90%. On March 22, Heyuan biology and Junpu intelligence will land on the science and innovation board. There are 401 listed companies on the science and innovation board, with a total initial fund-raising of more than 560 billion yuan and a total market value of nearly 5 trillion yuan. Kechuang board has become a market dominated by professional investors. According to statistics, as of December 2021, the trading proportion of professional investors on the science and Innovation Board was nearly 90%, which was significantly higher than that in December 2019 (professional investors accounted for 70%). (China Securities Network)
The company refinances “canal irrigation” hard technology. The “capital channel” continues to attract “capital flowing water”, the refinancing market of the science and innovation board is “hot”, and the mechanism of promoting science and innovation with capital is also “live”. From the opening of the market to the end of February 2022, a total of 58 companies on the science and Innovation Board disclosed 61 refinancing plans, with a total fund-raising of about 106.6 billion yuan, of which 32 chose fixed increase (including 2 small express), and 20 refinancing registrations such as Advanced Micro-Fabrication Equipment Inc.China(688012) have taken effect. In March, a number of science and technology innovation companies including Wuxi Chipown Micro-Electronics Limited(688508) , Shanghai Junshi Biosciences Co.Ltd(688180) etc. successively put forward fixed growth plans, or actively expand production, or increase research and development. (China Securities Network)
Heyuan biology successfully landed in the capital market. On March 22, Heyuan biology landed on the scientific innovation board and became the first share of A-share gene therapy. Heyuan biology has a comprehensive technical platform including molecular biology platform, experimental virus vector packaging platform, cell function research platform, SPF animal experiment platform, clinical gene therapy vector and cell therapy process development platform, and quality control technology research platform. The IPO of Heyuan biology raised 1.2 billion yuan, of which 1 billion yuan was used for the construction of Heyuan Zhizao precision medical industry base near the port. The first phase of the project is planned to be put into operation at the beginning of 2023 and the second phase is planned to be put into operation at the beginning of 2025. (China Securities Network)
Last week, the Shanghai Composite Index fell 1.19%, the Shenzhen Component Index fell 2.08%, the small and medium-sized board index fell 2.46%, the gem index fell 2.80%, and the Kechuang 50 fell 3.27%. Among the 402 companies on the Kechuang board, 107 companies rose and 295 led the decline.
Last week, a science and technology innovation enterprise was accepted as Chengdu Huawei, with a financing amount of 1.5 billion yuan. As of the latest, 715 enterprises have been accepted, of which 45 have been inquired, 13 have been approved at the municipal Party committee meeting, 44 have been submitted for registration, 422 have been effective and 153 have been terminated.
Last week, the non scientific innovation board fund declared. As of March 27, 2022, the number of science and Innovation Board funds has reached 156, including 19 equity funds and 137 hybrid funds.
